Madison Memory Study:
In a double-blinded, placebo-controlled trial, Prevagen demonstrated the ability to improve aspects of cognitive function in participants with either normal cognitive aging or very mild impairment, as determined by pre-trial screening. The group of participants taking Prevagen improved certain aspects of cognitive function according to computer-based testing. The adults were over 40 years old and took one capsule daily (10 mg) for 90 days.
Safety Study I
The main ingredient in Prevagen, apoaequorin, was evaluated for safety using a toxicity study, a common method for evaluating dietary supplements. In doses much higher than can be reasonably consumed (4,000 times the recommended daily amount of Prevagen Regular Strength) apoaequorin showed no adverse effects when taken orally.
Safety Study II
In a separate safety study, Apoaequorin has not shown to have any significant risk of allergic reactivity when ingested.
Ongoing Research Partnership
Quincy Bioscience has had a long standing sponsored research agreement with the University of Wisconsin-Milwaukee Neuroscience department and the laboratory of Dr. James R. Moyer.